Industry Portals
Medical Device Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Candid View of M&A (ICIS Chemical Business November 7 – November 12, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of financing trends in the first three quarters of 2026 and the future outlook in 2026.
Galien Foundation Forum (October 29, 2026) Interview with Peter Young, CEO of Young & Partners
Peter Young, CEO of Young & Partners was interviewed at the Galien Foundation Forum.
Young & Partners 39th Annual Senior Chemical Executive Conference: Paul Triolo – “The State of Geopolitics and the U.S. China Relationship”
Paul Triolo, Partner, Global Technology Policy Lead, Albright Stonebridge Group
Young & Partners 39th Annual Senior Chemical Executive Conference: Stephen Floyd – “Current Chemical Stock Market and Financing Trends”
Stephen Floyd, Managing Director, Young & Partners
Young & Partners 39th Annual Senior Chemical Executive Conference: Yasheng Huang – “China: Key Perspectives”
Yasheng Huang, Professor of Global Economics and Management, MIT Sloan School
Young & Partners 39th Annual Senior Chemical Executive Conference: Alex Lidback – “Shifting Industry Structural Dynamics and the Keys to Winning”
Alex Lidback, VP - Head of Chemical Analytics, ICIS
Young & Partners 39th Annual Senior Chemical Executive Conference: Jason Bordoff – “The Energy Markets: The Path Going Forward”
Jason Bordoff, Director of the Center on Global Energy Policy at Columbia University School of International and Public Affair
A Steady Trajectory: Biopharma Review and Outlook (Pharmaceutical Executive October 2026 Issue)
Young & Partners reviews our analysis of M&A trends in the first half of 2026 and the future outlook for 2026.
Chemical Financing Activity Mixed (ICIS Chemical Business August 7 – August 13, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of financing trends in the first half of 2026 and the future outlook in 2026.
A Survey of Senior Chemical Industry Executives
Young & Partners shares with our analysis of the current and future sentiment and outlook of chemical industry executives in 2026.
Chemical M&A Surges (ICIS Chemical Business July 31, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
Cautious Momentum: Biopharma Review and Outlook (Pharmaceutical Executive March 2026)
Young & Partners shares with Pharmaceutical Executive on our analysis of M&A trends for Pharmaceuticals and Biotech in 2025 and the future outlook of M&A in 2026.
Chemicals M&A To See Upturn in 2026 (Chemical Week Feb 2 – Feb 9, 2026)
Young & Partners is interviewed by Chemical Week on our analysis of M&A trends in 2025 and the future outlook in 2026.
The Good, The Bad, and the Ugly (ICIS Chemical Business Jan 30 – Feb 5, 2026)
Young & Partners reports on our analysis of chemical stock market and financing trends for 2025 and the future outlook in 2026.
Signs of Revival in Chemical M&A (ICIS Chemical Business Jan 23 – Jan 29, 2026)
Young & Partners reports on our analysis of M&A markets for 2025 and the future outlook for Chemical M&A.
Pharmaceutical Executive Academy: The Impact of AI on the Life Science Industry with Najat Khan
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Financing Markets Mixed, Equities Lag (ICIS Chemical Business Nov 27 – Dec 4, 2025)
Young & Partners reports on our analysis of the debt and equity financing markets for the first three quarters of 2025 and the future outlook for Chemical financings.
Chemical M&A Mixed, Sideways (ICIS Chemical Business Nov 21 – Nov 27, 2025)
Young & Partners reports on our analysis of the M&A markets for the first three quarters of 2025 and the future outlook for Chemical M&A.
Young & Partners 2025 Pharmaceutical Executive Summit: Will China Overtake the West in Drug Development?
Michael Christel, Group Managing Editor, Pharmaceutical Executive, Pharmaceutical Commerce and Applied Clinical Trials, MJH Life Sciences Najat Khan, Chief R&D Officer and Chief Commercial Officer, Recursion Pharmaceuticals William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer Peter Young, CEO and President, Young & Partners
Young & Partners 2025 Pharmaceutical Executive Summit: Fireside Chat with Dr. William Pao, author of “Breakthrough: The Quest for Life-Changing Medicines
William Pao, CEO, Revelio Therapeutics, Former Chief Development Officer, Pfizer